Estimated End-Tidal Sevoflurane Concentration to Maintain Optimal Anesthetic Depth During Cardiopulmonary Bypass: A Meta-Analysis

Read full text
Authors: Sou Hyun Lee, Tae Hoon Kang, Sungah Yoo, Kyungmi Kim
Cited by: 0
References: 28

Abstract

Background/Objectives: Volatile anesthetic dosing during cardiopulmonary bypass (CPB) is poorly standardized. We estimated the end-tidal sevoflurane (ETsevo) concentration required to maintain adequate anesthesia during CPB and investigated the effects of age and body temperature. Methods: This study is a PRISMA-compliant, PROSPERO-registered meta-analysis. PubMed, Embase, and the Cochrane Library were searched. Prospective studies of adults who underwent cardiac surgery with CPB and receiving sevoflurane were included. Primary outcome was mean ETsevo concentration when bispectral index (BIS) was 40–60. Three-level random-effects meta-analytic models with robust variance estimation were used to pool repeated measurements within studies. Age and body temperature were then examined as study-level moderators. Risk of bias was determined using ROBINS-I. Results: Five studies (n = 129) fulfilled the criteria. Pooled ETsevo during CPB was 0.88 vol% (95% confidence interval [CI] 0.29 to 1.46; p = 0.02) with substantial heterogeneity (I2 = 87.6%). Body temperature was not a significant moderator (difference 0.26 vol%; 95% CI −1.12 to 1.64; p = 0.27). Higher mean age was associated with lower ETsevo, evidenced by the finding that patients with a mean age of >62.0 years required 0.45 vol% less ETsevo (95% CI −0.78 to −0.13; p = 0.01), and sensitivity analysis revealed a 0.05 vol% decrease per additional year. Conclusions: To maintain BIS at 40–60 during CPB, the estimated ETsevo requirement is 0.88 vol% (minimum alveolar concentration 0.53–0.58 in patients in their 60s). Requirements decreased with age, and body temperature exerted no detectable effect.

Fields of Study & Subjects

Anesthesia and Sedative Agents Biomedical and Chemical Research Cardiac and Coronary Surgery Techniques

Publication details

Journal / source
Biomedicines
Volume
14
Issue
3
Pages
535–535
Publication date
27 February 2026
Language
EN